Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Yissum Introduces a Pioneering Vaccine Against CME

Published: Thursday, December 13, 2012
Last Updated: Thursday, December 13, 2012
Bookmark and Share
Results showing the effectiveness of the vaccine in dogs were recently published in the journal Vaccine.

Canine monocytic ehrlichiosis (CME) is a major, potentially fatal, tick-borne dog disease prevalent worldwide.

No commercial vaccine for the disease is currently available and tick control is the main preventive measure against the disease.

Now, Yissum Research and Development Company of the Hebrew University of Jerusalem, introduces a vaccine against CME, which was developed by Professors Shimon Harrus and Gad Baneth, from the Koret School of Veterinary Medicine, Faculty of Agricultural, Food and Environmental Quality Sciences at the Hebrew University of Jerusalem.

The vaccine has proven effective in an experimental study in dogs, which was recently published in the prestigious journal Vaccine.

Profs. Harrus and Baneth developed the vaccine from a proprietary attenuated strain of Ehrlichia canis, the bacteria that causes CME. The efficiency of the attenuated strain as a vaccine was assessed on 12 dogs, which were divided into three groups.

Four dogs were inoculated (vaccinated) with the attenuated Ehrlichia strain twice, four dogs only once and the last group of four dogs served as the control group.

The vaccinated dogs showed no clinical signs after the inoculation, suggesting that the novel vaccine is safe for use and does not induce adverse effects.

When the dogs were infected with a virulent Ehrlichia field strain, the control dogs all developed a severe disease, whereas only three of the eight vaccinated dogs presented mild transient fever and the rest remained healthy.

"Canine monocytic ehrlichiosis is a serious dog disease that can lead to death. Current treatment includes supportive care, and a harsh and lengthy antibiotic treatment, which may not be effective in chronic infections. The vaccine developed by Profs. Harrus and Baneth is the first vaccine to prove effective against this disease," said Yaacov Michlin, CEO of Yissum.

Michlin continued, "The current lack of vaccine for CME, the growing awareness of the market and the growing market needs make this invention particularly attractive, and Yissum is currently looking for commercial partners for further development and commercialization purposes."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Yissum Introduces a Novel Technology for Drug Screening and Testing of Orphan Diseases
Novel technology utilizes stem cells as models for genetic disorders and enables large scale screening of small molecule drugs.
Saturday, August 08, 2015
ISA Scientific, Yissum, Hadasit and KIR to Collaborate
Licensing and collaboration agreement on treating diabetes and other serious health conditions with cannabidiol.
Friday, April 03, 2015
Yissum Introduces a Novel Method for Treating Cancer Based on Vif
The novel method uses a peptide derived from HIV to increase the sensitivity of cancer cells to radiotherapy and chemotherapy.
Tuesday, July 10, 2012
Yissum to Collaborate with BioConnections
The novel kits enable direct detection of "superbugs" and provide instant guidelines for appropriate treatment.
Tuesday, February 28, 2012
Yissum Announces Long-Term Multi-Project Research and License Collaboration with Roche
Roche has selected six promising research projects for the treatment of metabolic diseases, initiated by Hebrew University researchers.
Monday, October 26, 2009
Yissum Licenses Stem Cell Technologies for Spinal Therapy to TheraCell
The technology will help to further develop and commercialize the technology for advanced regenerative medicine procedures.
Wednesday, July 15, 2009
Yissum Signs a Collaboration Agreement with Aurum Ventures MKI
Collaboration focuses on the development of liver-bypassing oral drug delivery nanotechnology.
Monday, June 29, 2009
Atox Bio and Fast-Track Drugs and Biologics Sign an R&D Collaboration Agreement
The collaboration is funded by the Israel-U.S. binational BIRD Foundation aimed at the development of therapeutics for sepsis and septic shock.
Thursday, June 25, 2009
Yissum Introduces Novel Compound for the Treatment of Osteoporosis
Hebrew University researchers have invented a new drug candidate that both inhibits bone resorption and stimulates bone formation.
Thursday, June 25, 2009
Z-Cube and Yissum Sign a Licensing Agreement for the Development of a Nanotechnology Drug Delivery System
Z-Cube has received the worldwide exclusive right to develop and commercialize the technology for the treatment of pain.
Monday, June 01, 2009
Yissum Announces the Launch of the Hebrew University's Genetic Resource for Studies of Common Diseases
The Hebrew University Genetic Resource platform includes 15,000 DNA samples of Ashkenazi Jews.
Thursday, March 20, 2008
Yissum and Eucalyptus Collaborate to Develop Small Molecule for the Treatment of Neurodegenerative Diseases
The licensed molecule is an antioxidant that overcomes the blood-brain barrier.
Thursday, January 10, 2008
Yissum Spins-Off Nanolymf to Advance Breakthrough Liver-Bypassing Oral Drug Delivery Technology
Nanolymf is dedicated to advancing a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administrated lipophilic drugs.
Thursday, January 10, 2008
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!